Ether Compounds Modulating Cytokine Activity for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and cancers often involve systemic delivery of cytokines like IL-2, which have short half-lives and significant side effects, and target proteins such as TNFα, IL-6, aiolos, ikaros, and CK1α, where localized expression and specific protein degradation are challenging.
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salt, which can inhibit the activity of cytokines like IL-1β, IL-2, IL-6, TNFα, aiolos, ikaros, and CK1α, allowing for localized expression and specific protein degradation to treat inflammatory diseases and cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic delivery of cytokines like IL-2 is used, then therapeutic levels can be achieved, but side effects increase and half-life remains short
Solution Approach 1:
The invention divides the treatment approach into two components: (1) systemic delivery of a low dose cytokine or its analog to achieve baseline therapeutic effect, and (2) local delivery of a protein degradation inhibitor to specific tissues to amplify the effect locally and reduce systemic side effects. This segmentation allows different dosing strategies for different locations, resolving the contradiction between achieving therapeutic levels systemically and minimizing side effects.
Solution Approach 2:
The protein degradation inhibitor acts as an intermediary that amplifies the effect of the cytokine locally. By inhibiting the proteasome or ubiquitin system in specific tissues, the inhibitor mediates between the systemic cytokine delivery and the desired local therapeutic effect, allowing low systemic doses to produce high local effects without proportionally increasing side effects.
2Object-affected harmful factors
If local delivery of cytokines is used, then side effects are minimized, but achieving sufficient therapeutic levels becomes challenging
Solution Approach 1:
The invention merges two delivery strategies: systemic cytokine delivery and local protein degradation inhibition. By combining these approaches, the system achieves both low side effects (from localized action) and high therapeutic efficacy (from amplified local effect and sustained presence). The merger allows the weaknesses of each individual approach to be compensated by the strengths of the other.
Solution Approach 2:
The treatment uses a composite approach combining a cytokine (or analog) with a protein degradation inhibitor. This composite strategy creates a synergistic effect where the cytokine provides the primary therapeutic action and the degradation inhibitor enhances and prolongs its effect locally, achieving both safety and efficacy simultaneously.
3Reliability
If high doses of IL-2 are administered, then therapeutic levels are achieved, but the short half-life requires frequent large injections
Solution Approach 1:
The protein degradation inhibitor is administered locally to pre-block protein degradation pathways before and during cytokine treatment. This preliminary action creates a protective environment that slows cytokine clearance, effectively extending half-life without requiring dose adjustments or frequent injections. The inhibitor prepares the tissue to retain and utilize the cytokine more efficiently.
Solution Approach 2:
The invention changes the kinetic parameters of cytokine action by locally inhibiting degradation. This alters the half-life and persistence of the cytokine in target tissues, transforming the pharmacokinetic profile from short-acting to sustained-acting locally, thereby reducing the frequency and complexity of dosing regimens.
Data Source
AI summary
The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided.